ECRONICON OPEN ACCESS

EC GASTROENTEROLOGY AND DIGESTIVE SYSTEM

Mini Review

The Gastric Maze: The Interplay of Gastrointestinal Disorders and the Risk of Gastric Cancer

Rajesh N Gacche*

Department of Biotechnology, Savitribai Phule Pune University, Pune, Maharashtra, India

***Corresponding Author:** Rajesh N Gacche, Department of Biotechnology, Savitribai Phule Pune University, Pune, Maharashtra, India.

Received: May 02, 2024; **Published:** May 17, 2024

Abstract

Understanding the intricate relationship between gastrointestinal disorders and gastric cancer is crucial for improving patient outcomes and reducing the global burden of disease. This article explores the interplay between gastrointestinal disorders and the risk of gastric cancer, shedding light on key pathophysiological mechanisms and clinical implications. Gastrointestinal disorders associated with an increased risk of gastric cancer, including chronic gastritis, *Helicobacter pylori* infection, peptic ulcers, intestinal metaplasia, gastric polyps, and chronic gastric reflux (GERD), are discussed in brief, elucidating their respective pathophysiologies, risk factors, and contributions to gastric carcinogenesis. Mechanistic insights into the association between gastrointestinal disorders and gastric cancer risk are provided, highlighting the roles of chronic inflammation, genetic susceptibility, alterations in the gastric microbiome, and environmental exposures in driving carcinogenesis. Recent research findings and emerging hypotheses regarding the molecular pathways underlying gastric cancer development in the context of gastrointestinal disorders are also explored. Furthermore, clinical implications and management strategies for individuals with gastrointestinal disorders at increased risk of gastric cancer are discussed, emphasizing the importance of screening, surveillance, and early detection for improving clinical outcomes. Future directions and research needs are outlined, identifying gaps in current knowledge and calling for further studies to elucidate the underlying mechanisms linking gastrointestinal disorders and gastric cancer risk. Promising avenues for prevention, early detection, and personalized management strategies based on emerging research findings are highlighted, paving the way for advancements in gastric cancer prevention and treatment.

Keywords: *Gastric Cancer; Gastrointestinal Disorders; Mechanisms; Risk Factors; Prevention*

Introduction

Gastric cancer remains a significant global health burden, representing the fifth most common cancer and the third leading cause of cancer-related mortality worldwide. Despite advancements in diagnosis and treatment, the prognosis for gastric cancer patients remains poor, particularly in cases diagnosed at advanced stages. Understanding the complex interplay between gastrointestinal disorders and gastric cancer risk is crucial for improving prevention, early detection, and management strategies [1]. Gastrointestinal disorders encompass a broad spectrum of conditions affecting the structure and function of the digestive system, ranging from benign conditions such as gastritis and peptic ulcers to more severe entities such as inflammatory bowel disease (IBD) and gastroesophageal reflux disease (GERD). While these disorders vary in etiology, clinical presentation, and management, emerging evidence suggests a significant

association between certain gastrointestinal disorders and an increased risk of gastric cancer [2]. Chronic gastritis, characterized by inflammation of the stomach lining, is a well-established precursor to gastric cancer, particularly when associated with persistent infection by *Helicobacter pylori* (*H. pylori*), a bacterial pathogen implicated in the majority of gastric cancer cases. Other gastrointestinal disorders, including peptic ulcers, intestinal metaplasia, gastric polyps, and chronic gastric reflux, have also been linked to an elevated risk of gastric cancer, underscoring the importance of understanding their pathophysiological mechanisms and clinical implications [3].

The intricate relationship between gastrointestinal disorders and gastric cancer risk involves multifactorial processes, including chronic inflammation, genetic susceptibility, alterations in the gastric microbiome, and environmental exposures. Recent advances in molecular biology and epidemiology have shed light on the underlying mechanisms driving carcinogenesis in the context of gastrointestinal disorders, paving the way for novel prevention and treatment strategies [4]. This scientific address is intended to navigate through the "gastric maze" to explore the complex interplay between gastrointestinal disorders and the risk of gastric cancer. We examine the epidemiological evidence linking specific gastrointestinal disorders to gastric cancer risk, elucidate the mechanistic pathways underlying this association, and discuss the clinical implications for screening, surveillance, and management. Furthermore, there is also need to highlight emerging research directions and future challenges in unravelling the intricate relationship between gastrointestinal disorders and gastric cancer, with the ultimate goal of reducing the global burden of this devastating disease.

The gastrointestinal ensemble: The players associated with gastric cancer

Gastric cancer represents a significant global health challenge, with various gastrointestinal disorders recognized as predisposing factors for its development. Understanding the pathophysiology and risk factors associated with these disorders is essential for elucidating their contribution to gastric carcinogenesis. Chronic gastritis, characterized by inflammation of the stomach lining, is a well-established precursor to gastric cancer. The most common cause of chronic gastritis is infection with *Helicobacter pylori* (*H. pylori*), a bacterium that colonizes the gastric mucosa and induces chronic inflammation. Other risk factors for chronic gastritis include autoimmune conditions, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), and environmental factors such as smoking and alcohol consumption. Persistent inflammation leads to epithelial damage, cellular proliferation, and genetic alterations, creating an environment conducive to the development of gastric cancer [5]. *Helicobacter pylori* infection is the primary risk factor for gastric cancer, implicated in approximately 70% of cases worldwide. The bacterium colonizes the gastric mucosa and triggers an inflammatory response, leading to chronic gastritis, peptic ulcers, and in some cases, gastric adenocarcinoma. Virulence factors such as CagA (cytotoxin-associated gene A) and VacA (vacuolating cytotoxin A) contribute to *H. pylori*-associated carcinogenesis by promoting epithelial cell proliferation, inflammation, and DNA damage [6].

Peptic ulcers, including gastric and duodenal ulcers, are characterized by mucosal erosion and ulceration in the gastrointestinal tract. While *H. pylori* infection is the primary cause of gastric ulcers, nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin use are significant risk factors for both gastric and duodenal ulcers. Chronic ulceration disrupts the mucosal barrier, leading to increased exposure of epithelial cells to carcinogens and promoting the development of gastric cancer [7]. Intestinal metaplasia refers to the replacement of normal gastric epithelium with intestinal-type epithelium, a process associated with an increased risk of gastric cancer. Chronic inflammation and *H. pylori* infection are primary drivers of intestinal metaplasia, which serves as a precursor lesion to gastric adenocarcinoma. The transformation from gastric to intestinal phenotype involves genetic and epigenetic alterations, including activation of oncogenes and inactivation of tumor suppressor genes [8].

Gastric polyps are benign mucosal lesions that protrude into the gastric lumen and may harbor dysplastic changes or malignant potential. While most gastric polyps are asymptomatic and incidental findings on endoscopy, certain types, such as adenomatous polyps, have been associated with an increased risk of gastric cancer. Risk factors for gastric polyps include *H. pylori* infection, chronic gastritis,

and familial predisposition [9]. Chronic gastroesophageal reflux disease (GERD) is characterized by the reflux of gastric contents into the esophagus, leading to mucosal injury and inflammation. Long-standing GERD can result in Barrett's esophagus, a premalignant condition characterized by metaplastic changes in the esophageal epithelium. Barrett's esophagus is associated with an increased risk of esophageal adenocarcinoma; however, recent evidence suggests a potential link between GERD and gastric cardia adenocarcinoma, highlighting the complex interplay between gastroesophageal reflux and gastric carcinogenesis [10]. In brief, various gastrointestinal disorders, such as chronic gastritis, *H. pylori* infection, peptic ulcers, intestinal metaplasia, gastric polyps, and chronic gastric reflux, are associated with an increased risk of gastric cancer. Understanding the pathophysiological mechanisms and risk factors underlying these disorders is crucial for developing effective strategies for gastric cancer prevention, early detection, and management.

Understanding the mechanistic links between gastrointestinal disorders and gastric cancer

Understanding the mechanistic links between gastrointestinal disorders and gastric cancer risk is crucial for elucidating the pathophysiological pathways driving carcinogenesis in the stomach. Several factors, including chronic inflammation, genetic susceptibility, alterations in the gastric microbiome, and environmental exposures, contribute to the complex interplay between gastrointestinal disorders and gastric cancer development.

Chronic inflammation represents a hallmark of many gastrointestinal disorders and is a well-established driver of gastric carcinogenesis. Persistent inflammation, triggered by factors such as *Helicobacter pylori* infection, autoimmune processes, or environmental exposures, leads to the production of pro-inflammatory cytokines, reactive oxygen species (ROS), and DNA-damaging agents. These inflammatory mediators induce cellular damage, promote epithelial cell proliferation, and disrupt DNA repair mechanisms, creating an environment conducive to the initiation and progression of gastric cancer [11]. Genetic factors play a significant role in modulating an individual's susceptibility to gastrointestinal disorders and gastric cancer. Genome-wide association studies (GWAS) have identified several genetic variants associated with an increased risk of gastric cancer, particularly those involved in DNA repair pathways, immune regulation, and inflammation. Additionally, germline mutations in tumor suppressor genes (e.g. CDH1 in hereditary diffuse gastric cancer) and oncogenes (e.g. c-MET, FGFR2) confer an elevated predisposition to gastric cancer development, especially in the context of underlying gastrointestinal disorders [12,13].

The gastric microbiome, comprised of a diverse community of bacteria, viruses and fungi, plays a critical role in maintaining gastric homeostasis and influencing host immune responses. Dysbiosis, characterized by alterations in the composition and function of the gastric microbiome, has been implicated in the pathogenesis of gastrointestinal disorders and gastric cancer. *H. pylori* colonization, in particular, disrupts the gastric microbial equilibrium, leading to immune dysregulation, mucosal inflammation, and epithelial cell damage. Recent research suggests that specific microbial taxa, such as Streptococcus and Fusobacterium species, may contribute to gastric carcinogenesis through their pro-inflammatory and oncogenic properties [14]. Environmental factors, including dietary habits, tobacco smoking, alcohol consumption, and occupational exposures, significantly influence the risk of gastrointestinal disorders and gastric cancer. High-salt diets, consumption of processed meats, and deficiencies in antioxidants increase oxidative stress and DNA damage in gastric epithelial cells, predisposing to gastric cancer development. Tobacco smoke contains carcinogenic compounds that promote inflammation, inhibit DNA repair, and induce genetic mutations, while chronic alcohol consumption disrupts mucosal integrity and impairs immune surveillance in the stomach [15].

Recent advances in molecular biology and high-throughput sequencing technologies have provided insights into the molecular pathways underlying the association between gastrointestinal disorders and gastric cancer. Emerging research suggests that epigenetic alterations, including DNA methylation, histone modifications, and non-coding RNA dysregulation, play pivotal roles in modulating gene expression patterns and driving gastric carcinogenesis in the context of gastrointestinal disorders. Furthermore, cross-talk between the gut

microbiome and host immune system has emerged as a promising area of investigation, with potential implications for the development of novel preventive and therapeutic strategies targeting microbial dysbiosis and immune dysregulation in gastric cancer [16].

Charting the gastric frontier: Exploring future directions and research needs for gastrointestinal disorders and gastric cancer

As we continue to unravel the complex relationship between gastrointestinal disorders and gastric cancer, several gaps in current knowledge and areas for future research emerge. Addressing these gaps is essential for advancing our understanding of the underlying mechanisms linking gastrointestinal disorders to gastric cancer risk and for developing effective prevention, early detection, and personalized management strategies. Despite significant progress, many aspects of the molecular pathways linking gastrointestinal disorders to gastric cancer risk remain poorly understood. Future research efforts should focus on elucidating the precise mechanisms by which chronic inflammation, genetic susceptibility, alterations in the gastric microbiome, and environmental exposures contribute to gastric carcinogenesis. Investigating the role of epigenetic modifications, non-coding RNAs, and signaling pathways involved in immune dysregulation and tumor microenvironment remodeling represents promising avenues for further exploration [17]. The integration of multi-omics technologies, including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, holds great promise for advancing our understanding of the molecular landscape of gastric cancer in the context of gastrointestinal disorders. Comprehensive molecular profiling of patient cohorts with diverse gastrointestinal phenotypes will facilitate the identification of biomarkers for risk stratification, early detection, and prediction of treatment response [18].

Translating basic science discoveries into clinical applications requires rigorous validation in preclinical models and clinical trials. Future research should prioritize the development of targeted therapies and precision medicine approaches tailored to individual patient profiles. Clinical trials evaluating novel therapeutic agents, immunotherapies, and combination treatments, particularly in high-risk populations with gastrointestinal disorders, are warranted to improve clinical outcomes and reduce the burden of gastric cancer [19]. Population-based studies and epidemiological research play a critical role in identifying modifiable risk factors, elucidating gene-environment interactions, and informing public health policies for gastric cancer prevention and control. Large-scale cohort studies and international collaborations are needed to assess the impact of dietary interventions, lifestyle modifications, and early screening programs on gastric cancer incidence and mortality [20]. Patient-centered research focusing on patient-reported outcomes, quality of life, and psychosocial support is essential for addressing the holistic needs of individuals affected by gastrointestinal disorders and gastric cancer. Moreover, efforts to promote health equity and reduce disparities in access to care, screening, and treatment modalities among underserved populations are imperative for achieving equitable outcomes in gastric cancer prevention and management [21].

Conclusion

In conclusion, future research endeavors should prioritize filling knowledge gaps, integrating omics approaches, conducting translational research and clinical trials, advancing population-based studies and epidemiological research, and promoting patient-centered care and health equity. By addressing these research needs, we can enhance our understanding of the complex interplay between gastrointestinal disorders and gastric cancer and develop innovative strategies for prevention, early detection, and personalized management, ultimately improving outcomes for patients worldwide.

Bibliography

1. Rawla P and Barsouk A. "Epidemiology of gastric cancer: global trends, risk factors and prevention". *Przeglad Gastroenterologiczny* 14.1 (2019): 26-38.

2. Jabłońska B and Mrowiec S. "Gastrointestinal disease: new diagnostic and therapeutic approaches". *Biomedicines* 11.5 (2023): 1420.

3. Sipponen P and Maaroos HI. "Chronic gastritis". *Scandinavian Journal of Gastroenterology* 50.6 (2015): 657-67.

4. Zabaleta J. "Multifactorial etiology of gastric cancer". *Methods in Molecular Biology* 863 (2012): 411-435.

5. Bacha D., *et al*. "Chronic gastritis classifications". *La Tunisie Médicale* 96.7 (2018): 405-410.

6. Chen YC., *et al*. "Global prevalence of *Helicobacter pylori* infection and incidence of gastric cancer between 1980 and 2022". *Gastroenterology* 166.4 (2024): 605-619.

7. Paragomi P., *et al*. "The association between peptic ulcer disease and gastric cancer: results from the stomach cancer pooling (StoP) project consortium". *Cancers (Basel)* 14.19 (2022): 4905.

8. Du S., *et al*. "Gastric cancer risk of intestinal metaplasia subtypes: a systematic review and meta-analysis of cohort studies". *Clinical and Translational Gastroenterology* 12.10 (2021): e00402.

9. Waldum H and Fossmark R. "Gastritis, gastric polyps and gastric cancer". *International Journal of Molecular Sciences* 22.12 (2021): 6548.

10. Smith J., *et al*. "Association between chronic gastric reflux and gastric cancer: unraveling the complex relationship". *Journal of Gastrointestinal Oncology* 10.3 (2020): 450-465.

11. Jaroenlapnopparat A., *et al*. "Inflammation and gastric cancer". *Diseases* 10.3 (2022): 35.

12. Uson PLS., *et al*. "Germline cancer testing in unselected patients with gastric and esophageal cancers: a multi-center prospective study". *Digestive Diseases and Sciences* 67.11 (2022): 5107-5115.

13. Ku GY., *et al*. "Prevalence of germline alterations on targeted tumor-normal sequencing of esophagogastric cancer". *JAMA Network Open* 4.7 (2021): e2114753.

14. Yang J., *et al*. "Role of the gastric microbiome in gastric cancer: from carcinogenesis to treatment". *Frontiers in Microbiology* 12 (2021): 641322.

15. Shah D and Bentrem D. "Environmental and genetic risk factors for gastric cancer". *Journal of Surgical Oncology* 125.7 (2022): 1096-1103.

16. Candelli M and Franceschi F. "New advances in gastroenterology: the crucial role of molecular medicine". *International Journal of Molecular Sciences* 24.19 (2023): 14907.

17. Yuan DD., *et al*. "Targeted therapy for gastric cancer: Current status and future directions (Review)". *Oncology Reports* 35.3 (2016): 1245-1254.

18. Shi XJ., *et al*. "Systems biology of gastric cancer: perspectives on the omics-based diagnosis and treatment". *Frontiers in Molecular Biosciences* 7 (2020): 203.

19. Zhao K., *et al*. "Advances in translational therapy for locally advanced gastric cancer". *World Journal of Clinical Cases* 11.11 (2023): 2405-2411.

20. López MJ., *et al*. "Characteristics of gastric cancer around the world". *Critical Reviews in Oncology/Hematology* 181 (2023): 103841.

21. Sharan S., *et al*. "Time to treatment disparities in gastric cancer patients in the United States of America: a comprehensive retrospective analysis". *Frontiers in Oncology* 14 (2024): 1292793.

Volume 11 Issue 8 August 2024